Menu Search
Equities

Biohit Oyj

BIOBV:HEX

Biohit Oyj

Actions
Health CareMedical Equipment and Services
  • Price (EUR)2.30
  • Today's Change-0.02 / -0.86%
  • Shares traded6.37k
  • 1 Year change+18.86%
  • Beta0.6453
Data delayed at least 15 minutes, as of Nov 21 2024 17:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in EUR

The one analyst offering a 12 month price target expects Biohit Oyj share price to rise to 2.70 in the next year from the last price of 2.30.
High17.4%2.70
Med17.4%2.70
Low17.4%2.70

Earnings history & estimates in EUR

On Oct 20, 2011, earnings of 0.03 per share.
Biohit Oyj reported annual 2023 earnings of 0.12 per share on Feb 14, 2024.
Average growth rate-107.30%
More ▼

Revenue history & estimates in EUR

of 9.80m. This missed the 11.00m estimate of the one analyst following the company. The same period last year the company did not report revenues.
Average growth rate+1.80%
Biohit Oyj had revenues for the full year 2023 of 13.10m. Last year the company did not report any revenues.
Average growth rate-10.45%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.